Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease

Edna Gordian, Kavitha Ramachandran, Isildinha M. Reis, Murugesan Manoharan, Mark S. Soloway, Rakesh Singal

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Background: Free circulating DNA (fcDNA) has been shown to be elevated in serum of prostate cancer patients compared with benign controls. However, studies evaluating the role of fcDNA as a biomarker in a " representative" patient group who have undergone prostate cancer screening are lacking. Our study examined the use of serum fcDNA levels as a biomarker of prostate cancer in such a setting. Methods: The study included 252 men, with prostate-specific antigen (PSA) levels >4 ng/mL and/or abnormal digital rectal exam. fcDNA levels in serum before prostate biopsy were quantitated by real-time PCR amplification of the glutathione S-transferase, pi, gene. Results: Patients with PSA ≤ 10 ng/mL with fcDNA > 180 ng/mL were at increased risk for prostate cancer compared with those with fcDNA ≤180 ng/mL (odds ratio, 4.27; 95% confidence interval, 2.05-8.88; P < 0.001; area under the curve, 0.742). The multivariate model including age, race, PSA, fcDNA, and interaction between fcDNA and PSA yielded a high negative predictive value of 93.1% and increased specificity of 33.1% compared with negative predictive value of 73.3% and specificity of 6.7% in the model excluding fcDNA. Conclusions: Our results indicate that fcDNA may improve the specificity of prostate cancer screening. Impact: Our study shows that adding fcDNA to prostate cancer screening can reduce the number of unnecessary prostate biopsies.

Original languageEnglish (US)
Pages (from-to)1984-1991
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Issue number8
StatePublished - Aug 2010

ASJC Scopus subject areas

  • Epidemiology
  • Oncology


Dive into the research topics of 'Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease'. Together they form a unique fingerprint.

Cite this